Borviz 2mg Injection
Product Info
Prescription required | Yes |
Marketer | Intas Pharmaceuticals Ltd |
Active Ingredient | Bortezomib (2mg) |
Storage | Store below 30°C |
Chemical Class | Phenylalanine Derivatives |
Habit Forming | No |
Therapeutic Class | ANTI NEOPLASTICS |
Action Class | Proteasome inhibitor |
User Rating | 4.4 |
User Reviews | 776 |
FAQ
Borviz 2mg Injection Reviews
Borviz 2mg is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Fatigue, nausea, vomiting, and loss of appetite are some common side effects of this medicine. You may be advised to drink plenty of fluids every day during the treatment. You should not drive or operate machinery as medicine may cause tiredness and dizziness. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.
Before taking Borviz 2mg, consult with your doctor if you have any liver, kidney, heart disease or bleeding problem. It is important to consult a doctor if you develop symptoms like memory loss or trouble in thinking. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
How Borviz 2mg Injection Works
How to Use Borviz 2mg Injection
Benefits of Borviz 2mg Injection
- In Mantle-cell lymphoma: Mantle-cell lymphoma is a cancer of the white blood cells in our body, also called non-Hodgkin's lymphoma. White blood cells are those cells that help us to fight infections. Borviz 2mg helps to restrict cancer growth and also blocks the action of other chemicals that are required for cancer growth and further spread. Avoid being in crowds and wash your hands often to prevent any infections. Have plenty of fluids, unless otherwise advised by the doctor not to.
- In Multiple myeloma: If you have multiple myeloma, your body is destroying bone faster than it is being replaced. This makes bones weak and painful and more likely to break. Borviz 2mg may be prescribed along with other cancer treatments such as chemotherapy. It is an important part of your treatment and increases the survival rate of people with multiple myeloma. This medicine will kill the cancerous cells and prevent their further growth as well as spread to other parts of the body. Follow your doctor’s instructions carefully to get the most benefit. Supplements of calcium and Vitamin D3 are also effective and may be prescribed if you do not have high blood calcium levels.
Uses of Borviz 2mg Injection
- Multiple myeloma
- Mantle-cell lymphoma
Borviz 2mg Injection Side Effects
Safety Tips
Quick Tips
- You may need to have blood tests to monitor your blood cells, platelets count, liver function and kidney function during treatment.
- Use an effective method of birth control to avoid pregnancy while taking this medication.
- Do not skip any dose and complete the course as suggested by your doctor.
- Inform your doctor immediately if you experience coughing, shortness of breath and swelling of feet.
- Borviz 2mg is given as an injection into veins or skin under the supervision of a healthcare professional.
References
- Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1742-43.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 958.
- Bortezomib [Prescribing Information]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2008.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 153-54.
- Central Drugs Standard Control Organisation (CDSCO).
- Bortezomib. Beerse Belgium: Janssen Pharmaceutica NV;